Rain Therapeutics Inc
Change company Symbol lookup
Select an option...
RAIN Rain Therapeutics Inc
BTCS BTCS Inc
IRDM Iridium Communications Inc
WDS Woodside Energy Group Ltd
MOS Mosaic Co
FRC-H First Republic Bank
VYM Vanguard High Dividend Yield Index Fund ETF Shares
SMBC Southern Missouri Bancorp Inc
ALG Alamo Group Inc
AFFCF American Future Fuel Corp
Go

Health Care : Pharmaceuticals |
Company profile

Rain Therapeutics Inc. (Rain) is a late-stage precision oncology company developing therapies that target oncogenic drivers. The Company’s lead product candidate, Milademetan (RAIN-32) is a small molecule, oral inhibitor of mouse double minute 2 (MDM2), which may be oncogenic in numerous cancers. RAIN-32 is being evaluated in an ongoing Phase III clinical trial in patients with LPS, as well as a Phase II tumor-agnostic basket trial in certain solid tumors (MANTRA-2). Rain is commencing a Phase II clinical trial of milademetan (MANTRA-3), for the treatment of patients with Merkel cell carcinoma. In addition to RAIN-32, the Company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52. The MANTRA-3 trial is designed to evaluate the efficacy of milademetan, as a monotherapy in patients with MCC. Rain is also developing a preclinical program focused on targeting RAD52 in the deoxyribonucleic acid damage repair pathway.

Closing Price
$7.72
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Heavy Day)
Volume:
190,063

10-day average volume:
135,936
190,063

Company Profile

Rain Therapeutics Inc. (Rain) is a late-stage precision oncology company developing therapies that target oncogenic drivers. The Company’s lead product candidate, Milademetan (RAIN-32) is a small molecule, oral inhibitor of mouse double minute 2 (MDM2), which may be oncogenic in numerous cancers. RAIN-32 is being evaluated in an ongoing Phase III clinical trial in patients with LPS, as well as a Phase II tumor-agnostic basket trial in certain solid tumors (MANTRA-2). Rain is commencing a Phase II clinical trial of milademetan (MANTRA-3), for the treatment of patients with Merkel cell carcinoma. In addition to RAIN-32, the Company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52. The MANTRA-3 trial is designed to evaluate the efficacy of milademetan, as a monotherapy in patients with MCC. Rain is also developing a preclinical program focused on targeting RAD52 in the deoxyribonucleic acid damage repair pathway.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
2.45x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

November 2022
Current Month
245.9K
Previous Month
266.8K
Percent of Float
1.35%
Days to Cover
3.0988 Days

Share Information

RAIN is in a share class of common stock
Float
23.4M
Shares Outstanding
35.1M
Institutions Holding Shares
61
74.98%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Avanish VellankiChmn.
  • Robert DoebelePres.
  • Richard Paul BryceExec.VP
  • Nelson D. Cabatuan
  • Franklin M. Berger

Address

Insider Trading

During the most recent quarter, 1M shares were bought in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.